Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DTIL 
Precision BioSciences Inc (DTIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: DTIL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30.5
1 Year Target Price $30.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.46% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.34M USD | Price to earnings Ratio - | 1Y Target Price 30.5 |
Price to earnings Ratio - | 1Y Target Price 30.5 | ||
Volume (30-day avg) 4 | Beta 1.47 | 52 Weeks Range 3.61 - 11.09 | Updated Date 07/14/2025 |
52 Weeks Range 3.61 - 11.09 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -42.99% | Operating Margin (TTM) -76248.27% |
Management Effectiveness
Return on Assets (TTM) -17.83% | Return on Equity (TTM) -50.81% |
Valuation
Trailing PE - | Forward PE 2.11 | Enterprise Value 1867641 | Price to Sales(TTM) 0.96 |
Enterprise Value 1867641 | Price to Sales(TTM) 0.96 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA -0.27 | Shares Outstanding 11088200 | Shares Floating 9117190 |
Shares Outstanding 11088200 | Shares Floating 9117190 | ||
Percent Insiders 11.07 | Percent Institutions 42.73 |
Upturn AI SWOT
Precision BioSciences Inc
Company Overview
History and Background
Precision BioSciences, Inc. was founded in 2006. It's a gene editing company focused on developing therapies using its proprietary ARCUS genome editing platform. They have evolved from agricultural applications to human therapeutics.
Core Business Areas
- Allogeneic CAR T Cell Therapy: Precision BioSciences develops off-the-shelf CAR T cell therapies targeting various cancers.
- In Vivo Gene Editing: Precision BioSciences works on in vivo gene editing approaches to directly target and modify genes within the body to treat genetic diseases.
- ARCUS Platform: Provides research and development of ARCUS platform.
Leadership and Structure
The company is led by Michael Amoroso (CEO) and has a typical corporate structure with a board of directors and various executive management positions overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- PBCAR0191: An allogeneic CAR T cell therapy targeting CD19 for B-cell malignancies. PBCAR0191 is in clinical development. Competitors include Kite Pharma (GILD) and Novartis (NVS) with their autologous CAR T therapies, as well as other companies developing allogeneic CAR T therapies such as Allogene (ALLO) and CRISPR Therapeutics (CRSP).
- PBCAR269A: An allogeneic CAR T cell therapy targeting PSMA for prostate cancer. PBCAR269A is in clinical development. Competitors include companies targeting PSMA with different therapeutic modalities.
Market Dynamics
Industry Overview
The gene editing and cell therapy industry is rapidly growing, driven by advancements in technology and increasing demand for targeted therapies for cancer and genetic diseases.
Positioning
Precision BioSciences aims to be a leader in allogeneic CAR T cell therapy and in vivo gene editing. Its ARCUS platform offers a unique approach compared to CRISPR-Cas9, potentially offering greater specificity and fewer off-target effects.
Total Addressable Market (TAM)
The TAM for gene editing and cell therapy is estimated to be in the tens of billions of dollars. Precision BioSciences is positioned to capture a portion of this market through its CAR T-cell therapy and in vivo gene editing programs.
Upturn SWOT Analysis
Strengths
- Proprietary ARCUS gene editing platform
- Allogeneic CAR T cell therapy programs
- In vivo gene editing capabilities
- Experienced management team
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Competition from established pharmaceutical companies
- Limited number of approved products
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of pipeline through new targets and indications
- Advancements in gene editing technology
- Regulatory approvals for lead product candidates
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene editing technologies
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- CRSP
- ALLO
- EDIT
- BEAM
Competitive Landscape
Precision BioSciences' ARCUS platform provides a potential advantage, but faces competition from established CRISPR-Cas9 companies and other allogeneic cell therapy developers. They need to differentiate with efficacy, safety, and cost-effectiveness.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth is characterized by R&D progress, securing partnerships, and advancing candidates through clinical trials. Financial growth is primarily tied to partnership payments and potential future product revenues.
Future Projections: Future growth relies on successful clinical trials and potential commercialization of its therapies. Analyst projections vary depending on pipeline progress and regulatory approvals.
Recent Initiatives: Recent strategic initiatives include focusing on key programs, streamlining operations, and pursuing strategic partnerships.
Summary
Precision BioSciences is a gene editing company with a unique ARCUS platform, but it faces challenges common to biotech companies, including clinical trial risks and high cash burn. The success of its CAR T cell and in vivo gene editing programs will determine its future. Strategic partnerships are crucial for funding and development. The company needs to demonstrate the superiority of ARCUS over other gene editing technologies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry news
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Precision BioSciences Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2019-03-28 | President, CEO & Director Mr. Michael Amoroso | ||
Sector Healthcare | Industry Biotechnology | Full time employees 107 | Website https://precisionbiosciences.com |
Full time employees 107 | Website https://precisionbiosciences.com | ||
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.